Previous 10 | Next 10 |
home / stock / mrvl / mrvl articles
Marvell Tech (NASDAQ:MRVL) has outperformed the market over the past 15 years by 1.17% on an annualized basis producing an average annual return of...
Needham analyst Quinn Bolton reiterated a Buy rating on Marvell Technology Inc (NASDAQ:MRVL) with a price target of $95. On Thu...
The semiconductor industry continues to navigate the complex geopolitical landscape, with U.S. companies maintaining a significant presence in the ...
BofA Securities analyst Vivek Arya reiterated a Buy rating on Marvell Technology, Inc. (NASDAQ:MRVL) with a price forecast of $...
BofA Securities analyst Vivek Arya’s top picks were Nvidia Corp (NASDAQ:NVDA) (Buy, price target of $1,100) and Broadcom Inc (NASDAQ:AVG...
Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter r...
Marvell Technology, Inc (NASDAQ:MRVL) will present its strategic approach to harness optical technology for AI and cloud data centers’ g...
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. Shares of Cintas Corporation (NASDAQ: CTAS) rose sharply ...
Marvell Technology, Inc (NASDAQ:MRVL) is braced to showcase multiple product offerings at OFC 2024, including probabilistic constellation...
News, Short Squeeze, Breakout and More Instantly...
Marvell Technology Inc. Company Name:
MRVL Stock Symbol:
NASDAQ Market:
Marvell Technology Inc. Website:
Calgary, Alberta--(Newsfile Corp. - July 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to report that, further to its press releases of May 16, 2024 and June 21, 2024, it has ...
2024-07-15 18:00:00 ET Broadcom (NASDAQ: AVGO) and Marvell Technology (NASDAQ: MRVL) usually don't attract as much attention as higher-growth chipmakers like Nvidia (NASDAQ: NVDA) . But like Nvidia, both diversified chip specialists are benefiting from the rapid ...
Calgary, Alberta--(Newsfile Corp. - July 9, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to highlight the recently published paper "Neuronal A2A receptor exacerbate...